The protective effect of rheumatic disease agents in COVID-19

被引：7
作者：
Valenzuela-Almada, Maria O. [1 ]
Putman, Michael S. [2 ]
Duarte-Garcia, Ali [1 ]
机构：
[1] Mayo Clin, Div Rheumatol, Rochester, MN 55905 USA
[2] Med Coll Wisconsin, Div Rheumatol, Milwaukee, WI USA
来源：
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2021年 / 35卷 / 01期
关键词：
COVID-19; Corticosteroids; IL-6; inhibitors; IL-1; TNF inhibitors; JAK inhibitors; GLUCOCORTICOIDS; THERAPY; TRIALS; SEPSIS;
D O I：
10.1016/j.berh.2021.101659
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical coronavirus disease 2019 (COVID-19). Notable examples include corticosteroids, interleukin 6 (IL-6), interleukin 1 (IL-1), Janus kinase (JAK), and tumor necrosis factor alpha (TNF-alpha) inhibitors. The aim of this narrative review is to analyze the mechanistic rationale and available evidence for these selected anti-rheumatic drugs for the treatment of COVID-19. Currently, only corticosteroids have consistently proven to be effective in decreasing mortality and are recommended in clinical guidelines for the treatment of severe and critical COVID-19. Multiple randomized controlled trials (RCTs) are ongoing to determine the role of other immunosuppressants. (C) 2021 Elsevier Ltd. All rights reserved.
引用
收藏
页数：10
相关论文
共 56 条
[1]   Hemophagocytic Lymphohistiocytosis [J].
Al-Samkari, Hanny ;
Berliner, Nancy .
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13, 2018, 13 :27-49
[2]  
Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
[3]   Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review [J].
Alzghari, Saeed K. ;
Acuna, Valerie S. .
JOURNAL OF CLINICAL VIROLOGY, 2020, 127
[4]   Glucocorticoids with or without Fludrocortisone in Septic Shock [J].
Schlegel, Amnon .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09) :893-893
[5]  
[Anonymous], ILARIS CANAKINUMAB
[6]  
[Anonymous], ACTEMRA TOCILIZUMAB
[7]  
[Anonymous], KINERET ANAKINRA
[8]   Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era [J].
Behrens, Edward M. ;
Koretzky, Gary A. .
ARTHRITIS & RHEUMATOLOGY, 2017, 69 (06) :1135-1143
[9]  
Bhimraj A, 2021, CLIN INFECT DIS
[10]   Cytokine storm and the prospects for immunotherapy with COVID-19 [J].
Calabrese, Leonard H. .
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2020, 87 (07) :389-393
123456